Helaina

Helaina is a New York-based biotechnology company using precision fermentation to produce human-equivalent bioactive proteins. Its first commercial product, effera, is a human-identical lactoferrin made in yeast that matches the amino acid sequence of the protein found in mother's milk. Founded in 2019 by food scientist Laura Katz, Helaina sells effera as a B2B ingredient to consumer wellness and supplement brands, targeting women's health, gut health, active nutrition and healthy aging. The company has raised roughly $84 million in equity funding, including a $45 million Series B in 2024.